Masazumi Arai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Masazumi Arai has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Hisayoshi Fujiwara
3 shared publicationsShinya Minatoguchi
Second Department of Internal Medicine, Gifu University School of Medicine, Gifu, Japan
3 shared publicationsGenzou Takemura
2 shared publicationsKazuaki Hashimoto
2 shared publications- Koji Ono
Department of Cardiology, Gifu Prefectural General Medical Center, Gifu, Japan
2 shared publications - Masanori Kawasaki
Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan
2 shared publications
Latest Publications
- Open Access
- 2 April 2015
- Published by Springer Nature in Cardiovascular Ultrasound
- Vol. 13 (1) , 17
Anti-inflammatory and morphologic effects of pitavastatin on carotid arteries and thoracic aorta evaluated by integrated backscatter trans-esophageal ultrasound and PET/CT: a prospective randomized comparative study with pravastatin (EPICENTRE study)
We sought to evaluate the effects of a strong lipophilic statin (pitavastatin) on plaque components and morphology assessed by transesophageal echocardiography (TEE) and transthoracic echocardiography (TTE), as well as plaque inflammation assessed by 18 F-fluorodeoxyglucose (FDG) PET/CT in the thoracic aorta and the carotid artery. Furthermore, we compared the effects of pitavastatin with those of mild hydrophilic statin (pravastatin). We examined atherosclerotic plaques in the thoracic aorta by TEE and those in the carotid artery by integrated backscatter (IBS)-TTE and PET/CT. We identified the target plaque, where there was macrophage infiltration and inflammation, by strong FDG uptake in the thoracic aorta and carotid arteries and measured maximum standard uptake values (max SUV) by PET/CT. We measured the intima-media thickness (IMT) and the corrected IBS (cIBS) values in the intima-media complex by TEE and TTE at the same site of FDG accumulation by PET/CT. Patients were randomly divided into two treatment groups: a pitavastatin group (PI group: n =10, 68.4 ± 5.1 years) and a pravastatin group (PR group: n =10, 63.9 ± 11.2 years). The same examinations were performed after six months at the same site in each patient. We used calculated target-to-background ratio (TBR) to measure max SUV of plaques and evaluated percent change of TBR. There was no significant difference in low density lipoprotein-cholesterol, TBR, IMT and cIBS values in plaques at baseline between the PI and PR groups. After treatment, there was greater improvement in TBR, cIBS values and IMT in the PI group than the PR group. The pravastatin treatment was less effective on plaque inflammation than pitavastatin treatment. This trend was the same in the carotid arteries and the thoracic aorta. Pitavastatin not only improved the atherosis as measured by IMT and cIBS values but also attenuated inflammation of plaques as measured by max SUV at the same site. The present study indicated that pitavastatin has stronger effects on the regression and stabilization of plaques in the thoracic aorta and carotid arteries compared with pravastatin.
- 2 April 2015
- Published by Springer Nature in Cardiovascular Ultrasound
- Vol. 13 (1) , 17
Open AccessAnti-inflammatory and morphologic effects of pitavastatin on carotid arteries and thoracic aorta evaluated by integrated backscatter trans-esophageal ultrasound and PET/CT: a prospective randomized comparative study with pravastatin (EPICENTRE study)
We sought to evaluate the effects of a strong lipophilic statin (pitavastatin) on plaque components and morphology assessed by transesophageal echocardiography (TEE) and transthoracic echocardiography (TTE), as well as plaque inflammation assessed by 18 F-fluorodeoxyglucose (FDG) PET/CT in the thoracic aorta and the carotid artery. Furthermore, we compared the effects of pitavastatin with those of mild hydrophilic statin (pravastatin). We examined atherosclerotic plaques in the thoracic aorta by TEE and those in the carotid artery by integrated backscatter (IBS)-TTE and PET/CT. We identified the target plaque, where there was macrophage infiltration and inflammation, by strong FDG uptake in the thoracic aorta and carotid arteries and measured maximum standard uptake values (max SUV) by PET/CT. We measured the intima-media thickness (IMT) and the corrected IBS (cIBS) values in the intima-media complex by TEE and TTE at the same site of FDG accumulation by PET/CT. Patients were randomly divided into two treatment groups: a pitavastatin group (PI group: n =10, 68.4 ± 5.1 years) and a pravastatin group (PR group: n =10, 63.9 ± 11.2 years). The same examinations were performed after six months at the same site in each patient. We used calculated target-to-background ratio (TBR) to measure max SUV of plaques and evaluated percent change of TBR. There was no significant difference in low density lipoprotein-cholesterol, TBR, IMT and cIBS values in plaques at baseline between the PI and PR groups. After treatment, there was greater improvement in TBR, cIBS values and IMT in the PI group than the PR group. The pravastatin treatment was less effective on plaque inflammation than pitavastatin treatment. This trend was the same in the carotid arteries and the thoracic aorta. Pitavastatin not only improved the atherosis as measured by IMT and cIBS values but also attenuated inflammation of plaques as measured by max SUV at the same site. The present study indicated that pitavastatin has stronger effects on the regression and stabilization of plaques in the thoracic aorta and carotid arteries compared with pravastatin.
- Open Access
- 27 December 2012
- Published by Springer Nature in Cardiovascular Ultrasound
- Vol. 10 (1) , 50
Motion of left atrial appendage as a determinant of thrombus formation in patients with a low CHADS2 score receiving warfarin for persistent nonvalvular atrial fibrillation
Background: The aim of this study was to define the independent determinants of left atrial appendage (LAA) thrombus among various echocardiographic parameters measured by Velocity Vector Imaging (VVI) in patients with nonvalvular atrial fibrillation (AF) receiving warfarin, particularly in patients with a low CHADS2 score. Methods: LAA emptying fraction (EF) and LAA peak longitudinal strain were measured by VVI using transesophageal echocardiography in 260 consecutive patients with nonvalvular persistent AF receiving warfarin. The patients were divided into two groups according to the presence (n=43) or absence (n=217) of LAA thrombus. Moreover, the patients within each group were further divided into subgroups according to a CHADS2 score ≤1. Results: Multivariate logistic regression analysis showed that LAAEF was an independent determinant of LAA thrombus in the subgroup of 140 with a low CHADS2 score. Receiver operating characteristics curve analysis showed that an LAAEF of 21% was the optimal cutoff value for predicting LAA thrombus. Conclusions: LAA thrombus formation depended on LAA contractility. AF patients with reduced LAA contractile fraction (LAAEF ≤21%) require strong anticoagulant therapy to avoid thromboembolic events regardless of a low CHADS2 score (≤1).
- 27 December 2012
- Published by Springer Nature in Cardiovascular Ultrasound
- Vol. 10 (1) , 50
Open AccessMotion of left atrial appendage as a determinant of thrombus formation in patients with a low CHADS2 score receiving warfarin for persistent nonvalvular atrial fibrillation
Background: The aim of this study was to define the independent determinants of left atrial appendage (LAA) thrombus among various echocardiographic parameters measured by Velocity Vector Imaging (VVI) in patients with nonvalvular atrial fibrillation (AF) receiving warfarin, particularly in patients with a low CHADS2 score. Methods: LAA emptying fraction (EF) and LAA peak longitudinal strain were measured by VVI using transesophageal echocardiography in 260 consecutive patients with nonvalvular persistent AF receiving warfarin. The patients were divided into two groups according to the presence (n=43) or absence (n=217) of LAA thrombus. Moreover, the patients within each group were further divided into subgroups according to a CHADS2 score ≤1. Results: Multivariate logistic regression analysis showed that LAAEF was an independent determinant of LAA thrombus in the subgroup of 140 with a low CHADS2 score. Receiver operating characteristics curve analysis showed that an LAAEF of 21% was the optimal cutoff value for predicting LAA thrombus. Conclusions: LAA thrombus formation depended on LAA contractility. AF patients with reduced LAA contractile fraction (LAAEF ≤21%) require strong anticoagulant therapy to avoid thromboembolic events regardless of a low CHADS2 score (≤1).
- 1 January 2003
- p. S39-47
Cross-talk among noradrenaline, adenosine and protein kinase C in the mechanisms of ischemic preconditioning in rabbits.
To date, there are two pathways discussed as a mechanism of ischemic preconditioning. Activation of protein kinase C by ischemic preconditioning increases adenosine release. The increased adenosine further activates protein kinase C through adenosine A1 receptors, and activated protein kinase C induces an infarct size-reducing effect through the opening of K(ATP) channels (pathway I). Meanwhile, activation of the alpha1b-adrenoceptor through increased interstitial noradrenaline by ischemic preconditioning is also associated with the ischemic preconditioning effect. However, the exact pathway of this is unknown, although it is postulated that protein kinase C and adenosine are cross-talking. Myocardial interstitial noradrenaline levels were measured in Japanese white rabbits using a microdialysis technique. Ischemic preconditioning was elicited by a single episode of 5 min ischemia and 5 min reperfusion. The infarct size was measured in rabbits subjected to 30 min ischemia and 48 h reperfusion. An increase in interstitial noradrenaline by ischemic preconditioning was not inhibited by an adenosine A1 receptor blocker (1,3-dipropyl-8-cyclopentylxanthine), but was inhibited by an adenosine A2 receptor blocker (3,7-dimethyl-1-(2-propynyl) xanthine) or protein kinase C inhibitors (staurosporine and polymyxin B). Interstitial noradrenaline was increased by an adenosine A2 receptor agonist (CGS21680) and the increase was inhibited by a protein kinase C inhibitor. The infarct size-reducing effect of ischemic preconditioning was inhibited by a selective alpha1b-adrenoceptor blocker (chloroethylclonidine) or a protein kinase C inhibitor, and that of tyramine, an inducer of noradrenaline, was inhibited by protein kinase C inhibitor. This suggests the presence of pathway II, indicating ischemic preconditioning --> activation of protein kinase C --> adenosine release --> pre-synaptic adenosine A2 receptors --> activation of protein kinase C in sympathetic nerve --> noradrenaline --> alpha1b-adrenoceptor --> activation of protein kinase C in myocytes --> infarct size-reducing effect. In addition, the ischemic preconditioning effect on infarct size was not inhibited by 1,3-dipropyl-8-cyclopentylxanthine, but was inhibited by 3,7-dimethyl-1-(2-propynyl) xanthine or chloroethylclonidine, suggesting the greater importance of pathway II compared with pathway I. Thus, pathway II plays an important role in the pathogenesis of the infarct size-reducing effect in ischemic preconditioning.
- 1 January 2003
- p. S39-47
Cross-talk among noradrenaline, adenosine and protein kinase C in the mechanisms of ischemic preconditioning in rabbits.
To date, there are two pathways discussed as a mechanism of ischemic preconditioning. Activation of protein kinase C by ischemic preconditioning increases adenosine release. The increased adenosine further activates protein kinase C through adenosine A1 receptors, and activated protein kinase C induces an infarct size-reducing effect through the opening of K(ATP) channels (pathway I). Meanwhile, activation of the alpha1b-adrenoceptor through increased interstitial noradrenaline by ischemic preconditioning is also associated with the ischemic preconditioning effect. However, the exact pathway of this is unknown, although it is postulated that protein kinase C and adenosine are cross-talking. Myocardial interstitial noradrenaline levels were measured in Japanese white rabbits using a microdialysis technique. Ischemic preconditioning was elicited by a single episode of 5 min ischemia and 5 min reperfusion. The infarct size was measured in rabbits subjected to 30 min ischemia and 48 h reperfusion. An increase in interstitial noradrenaline by ischemic preconditioning was not inhibited by an adenosine A1 receptor blocker (1,3-dipropyl-8-cyclopentylxanthine), but was inhibited by an adenosine A2 receptor blocker (3,7-dimethyl-1-(2-propynyl) xanthine) or protein kinase C inhibitors (staurosporine and polymyxin B). Interstitial noradrenaline was increased by an adenosine A2 receptor agonist (CGS21680) and the increase was inhibited by a protein kinase C inhibitor. The infarct size-reducing effect of ischemic preconditioning was inhibited by a selective alpha1b-adrenoceptor blocker (chloroethylclonidine) or a protein kinase C inhibitor, and that of tyramine, an inducer of noradrenaline, was inhibited by protein kinase C inhibitor. This suggests the presence of pathway II, indicating ischemic preconditioning --> activation of protein kinase C --> adenosine release --> pre-synaptic adenosine A2 receptors --> activation of protein kinase C in sympathetic nerve --> noradrenaline --> alpha1b-adrenoceptor --> activation of protein kinase C in myocytes --> infarct size-reducing effect. In addition, the ischemic preconditioning effect on infarct size was not inhibited by 1,3-dipropyl-8-cyclopentylxanthine, but was inhibited by 3,7-dimethyl-1-(2-propynyl) xanthine or chloroethylclonidine, suggesting the greater importance of pathway II compared with pathway I. Thus, pathway II plays an important role in the pathogenesis of the infarct size-reducing effect in ischemic preconditioning.
- 1 February 2002
- Vol. 39 (2) , 125-7
[A 27-year-old woman suffering repeated syncopal attacks. Congenital discrete subaortic stenosis Kelly, type I: membranous type].
- 1 February 2002
- Vol. 39 (2) , 125-7
[A 27-year-old woman suffering repeated syncopal attacks. Congenital discrete subaortic stenosis Kelly, type I: membranous type].
- 1 January 2001
- Published by Japanese Circulation Society in Japanese Circulation Journal
- Vol. 65 (10) , 907-911
Caspase-Dependent and Serine Protease-Dependent DNA Fragmentation of Myocytes in the Ischemia-Reperfused Rabbit Heart. These Inhibitors Do Not Reduce Infarct Size.
Some infarcted myocytes undergo caspase-dependent DNA fragmentation, but serine protease-dependent DNA fragmentation may also be involved. There is controversy regarding whether caspase inhibitors can reduce infarct size, so the present study investigated whether serine protease inhibitor can reduce the DNA fragmentation of infarcted myocytes and whether serine protease or caspase inhibitors attenuates myocardial infarct size in Japanese white rabbits without collateral circulation. Rabbits were subjected to 30-min coronary occlusion followed by 48-h reperfusion. A vehicle (dimethylsulfoxide, control group, n=8) or Z-Val-Ala-Asp(Ome)-CH2F (ZVAD-fmk, a caspase inhibitor, ZVAD group, 0.8 mg/kg iv at 20 min before coronary occlusion and 0.8 mg/kg at 90 min after reperfusion, n=8) or 3,4-dichloroisocoumarin (DCI, a serine protease inhibitor, 2 mg/kg iv at 20 min before coronary occlusion, DCI group, n=8) was administered. Animals were killed at 48 h after reperfusion for the detection of myocardial infarct size and at 4 h after reperfusion for the detection of dUTP nick end-labeling (TUNEL)-positive myocytes, the electrophoretic pattern of DNA fragmentation and ultrastructural analysis. The left ventricle (LV) was excised and sliced. The myocardial infarct size as a percentage of the area at risk was assessed by triphenyltetrazolium chloride staining. DNA fragmentation was assessed by in situ TUNEL at the light microscopic level. ZVAD and DCI significantly reduced the mean blood pressure during reperfusion without affecting heart rate. There was no significant difference in the % area at risk (AAR) of LV among the 3 groups (control: 26.3±3.0%; ZVAD: 25.6±2.6%; DCI: 25.6±2.0%). The % infarct size as a percentage of the AAR in the ZVAD group (41.3 ±4.5%) and the DCI group (50.4±3.8%) was not significantly different from the control group (43.5±4.5%). However, the percent DNA fragmentation in the infarcted area in the ZVAD (3.5±0.8%) and DCI groups (4.2±0.9%) was significantly reduced compared with the control group (10.7±1.9%). The DNA ladder pattern observed in the control group was attenuated in both the ZVAD and DCI groups. There was no difference in electron microscopic changes among the 3 groups. Serine protease-dependent DNA fragmentation is present in infarcted myocytes, in addition to caspase-dependent DNA fragmentation, but an infarct-size reducing effect was not observed with either of these inhibitors. (Jpn Circ J 2001; 65: 907 - 911)
- 1 January 2001
- Published by Japanese Circulation Society in Japanese Circulation Journal
- Vol. 65 (10) , 907-911
Caspase-Dependent and Serine Protease-Dependent DNA Fragmentation of Myocytes in the Ischemia-Reperfused Rabbit Heart. These Inhibitors Do Not Reduce Infarct Size.
Some infarcted myocytes undergo caspase-dependent DNA fragmentation, but serine protease-dependent DNA fragmentation may also be involved. There is controversy regarding whether caspase inhibitors can reduce infarct size, so the present study investigated whether serine protease inhibitor can reduce the DNA fragmentation of infarcted myocytes and whether serine protease or caspase inhibitors attenuates myocardial infarct size in Japanese white rabbits without collateral circulation. Rabbits were subjected to 30-min coronary occlusion followed by 48-h reperfusion. A vehicle (dimethylsulfoxide, control group, n=8) or Z-Val-Ala-Asp(Ome)-CH2F (ZVAD-fmk, a caspase inhibitor, ZVAD group, 0.8 mg/kg iv at 20 min before coronary occlusion and 0.8 mg/kg at 90 min after reperfusion, n=8) or 3,4-dichloroisocoumarin (DCI, a serine protease inhibitor, 2 mg/kg iv at 20 min before coronary occlusion, DCI group, n=8) was administered. Animals were killed at 48 h after reperfusion for the detection of myocardial infarct size and at 4 h after reperfusion for the detection of dUTP nick end-labeling (TUNEL)-positive myocytes, the electrophoretic pattern of DNA fragmentation and ultrastructural analysis. The left ventricle (LV) was excised and sliced. The myocardial infarct size as a percentage of the area at risk was assessed by triphenyltetrazolium chloride staining. DNA fragmentation was assessed by in situ TUNEL at the light microscopic level. ZVAD and DCI significantly reduced the mean blood pressure during reperfusion without affecting heart rate. There was no significant difference in the % area at risk (AAR) of LV among the 3 groups (control: 26.3±3.0%; ZVAD: 25.6±2.6%; DCI: 25.6±2.0%). The % infarct size as a percentage of the AAR in the ZVAD group (41.3 ±4.5%) and the DCI group (50.4±3.8%) was not significantly different from the control group (43.5±4.5%). However, the percent DNA fragmentation in the infarcted area in the ZVAD (3.5±0.8%) and DCI groups (4.2±0.9%) was significantly reduced compared with the control group (10.7±1.9%). The DNA ladder pattern observed in the control group was attenuated in both the ZVAD and DCI groups. There was no difference in electron microscopic changes among the 3 groups. Serine protease-dependent DNA fragmentation is present in infarcted myocytes, in addition to caspase-dependent DNA fragmentation, but an infarct-size reducing effect was not observed with either of these inhibitors. (Jpn Circ J 2001; 65: 907 - 911)
- 1 January 1991
- Published by Japanese Society for Dialysis Therapy in Journal of Japanese Society for Dialysis Therapy
- Vol. 24 (1) , 43-47
Clinical significance of .ALPHA.-human atrial natriuretic peptide in patients on maintenance dialysis.
心房性Na利尿ペプチド (α-hANP) の慢性血液透析 (HD) 患者と持続性自己管理腹膜透析 (CAPD) 患者の臨床的意義, とくにドライウエイトとの関係について検討した. 健常者10例 (男性5例, 女性5例, 平均年齢45.6歳), CAPD患者11例 (男性7例, 女性4例, 平均透析歴20.9か月), HD患者10例 (男性5例, 女性5例, 平均透析歴25.4か月) を対象とした. GAPDならびにHD患者の基礎疾患は全例, 慢性糸球体腎炎である. CAPD患者では心臓超音波検査施行日にα-hANPと限外濾過指数 (UFI) を測定した. HD患者ではHD前後に心臓超音波検査を, またHD前後ならびに次回HD前にα-hANPを測定した. また心エコー図法により左房径, 左室心筋重量を求めた. 以下の結論が得られた. 1. HD患者のα-hANPは健常者, CAPD患者に比較して上昇していた. 2. 左室心筋重量はCAPDとHD患者で増大していた. CAPD患者に比較してHD患者でその増大傾向は顕著であった. 3. 左房径とα-hANPとの間に有意の正相関が認められた. 4. HDによりα-hANPは減少した. α-hANPの減少率と体重減少率との間に有意の相関が認められた. 5. HD後と次回HD前のα-hANP増加率と体重増加率との間に有意な正相関が認められた. 6. UFIの低下しているCAPD患者のα-hANPは高値を示した. 以上よりα-hANPは慢性維持透析患者のドライウエイトの指標になり得るものと思われた. 具体的には, HD後ならびにCAPD中のα-hANP値が50ng/ml以下であればドライウエイトに到達している可能性が高いものと思われる.
- 1 January 1991
- Published by Japanese Society for Dialysis Therapy in Journal of Japanese Society for Dialysis Therapy
- Vol. 24 (1) , 43-47
Clinical significance of .ALPHA.-human atrial natriuretic peptide in patients on maintenance dialysis.
心房性Na利尿ペプチド (α-hANP) の慢性血液透析 (HD) 患者と持続性自己管理腹膜透析 (CAPD) 患者の臨床的意義, とくにドライウエイトとの関係について検討した. 健常者10例 (男性5例, 女性5例, 平均年齢45.6歳), CAPD患者11例 (男性7例, 女性4例, 平均透析歴20.9か月), HD患者10例 (男性5例, 女性5例, 平均透析歴25.4か月) を対象とした. GAPDならびにHD患者の基礎疾患は全例, 慢性糸球体腎炎である. CAPD患者では心臓超音波検査施行日にα-hANPと限外濾過指数 (UFI) を測定した. HD患者ではHD前後に心臓超音波検査を, またHD前後ならびに次回HD前にα-hANPを測定した. また心エコー図法により左房径, 左室心筋重量を求めた. 以下の結論が得られた. 1. HD患者のα-hANPは健常者, CAPD患者に比較して上昇していた. 2. 左室心筋重量はCAPDとHD患者で増大していた. CAPD患者に比較してHD患者でその増大傾向は顕著であった. 3. 左房径とα-hANPとの間に有意の正相関が認められた. 4. HDによりα-hANPは減少した. α-hANPの減少率と体重減少率との間に有意の相関が認められた. 5. HD後と次回HD前のα-hANP増加率と体重増加率との間に有意な正相関が認められた. 6. UFIの低下しているCAPD患者のα-hANPは高値を示した. 以上よりα-hANPは慢性維持透析患者のドライウエイトの指標になり得るものと思われた. 具体的には, HD後ならびにCAPD中のα-hANP値が50ng/ml以下であればドライウエイトに到達している可能性が高いものと思われる.